KREMEN2 and cancer: In addition, depletion of KREMEN2 (Supplementary Fig. 2c) reduced the viability of SMARCB1-deficient cell lines, but not that of SMARCB1-proficient cell lines, in the cancer cell line panel (Fig. 2c).